Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

216
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
216
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

55
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
55
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

552
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
552
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

72
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
72
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

38
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
38
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

28
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
28

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Swarm Intelligence in Drug Discovery Applications: Unlocking Deeper Insights on the Identification and Optimization of Potential Drug Candidates.

Drug design, development and therapy·2026
Same author

Learning to take it personally: Precision drug repurposing through patient-specific loss on knowledge graphs using Biobank data.

Journal of biomedical informatics·2026
Same author

Comparative evaluation of large language models in retrieving known and predicting novel drug combinations.

Journal of Alzheimer's disease : JAD·2026
Same author

KGiA: Drug repurposing through disease-aware knowledge graph augmentation.

Journal of biomedical informatics·2025
Same author

Tokenvizz: GraphRAG-Inspired Tokenization Tool for Genomic Data Discovery and Visualization.

bioRxiv : the preprint server for biology·2024
Same author

Systematic review and data synthesis on the treatment of sexual violence victimization by an intimate partner.

Journal of marital and family therapy·2023

Related Experiment Video

Updated: May 28, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K

Precision Drug Repurposing (PDR): Patient-level modeling and prediction combining foundational knowledge graph with

Çerağ Oğuztüzün1, Zhenxiang Gao2, Hui Li2

  • 1Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University, 10900 Euclid Ave, Cleveland, 44106, OH, USA; Department of Computer Science, Case Western Reserve University, 10900 Euclid Ave, Cleveland, 44106, OH, USA.

Journal of Biomedical Informatics
|February 14, 2025
PubMed
Summary
This summary is machine-generated.

Precision drug repurposing integrates individual patient data with knowledge graphs to discover personalized therapies. Polygenic Risk Scores significantly improved drug prioritization for conditions like Alzheimer's disease.

Keywords:
Alzheimer’s diseaseDrug repurposingGraph convolutional networkKnowledge graphsPolygenic risk scoresPrecision medicine

More Related Videos

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.6K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.1K

Related Experiment Videos

Last Updated: May 28, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.6K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.1K

Area of Science:

  • Biomedical Informatics
  • Pharmacogenomics
  • Computational Biology

Background:

  • Drug repurposing accelerates therapeutic development but struggles with individual patient variability.
  • Personalized medicine requires integrating patient-specific data for tailored drug discovery.

Purpose of the Study:

  • Introduce a Precision Drug Repurposing (PDR) framework for single-patient resolution.
  • Enable personalized drug discovery by integrating individual data with a biomedical knowledge graph.

Main Methods:

  • Developed a framework integrating UK Biobank data (Polygenic Risk Scores, biomarkers, medical history) with a biomedical knowledge graph.
  • Used Alzheimer's Disease as a case study, comparing patient-specific models against a foundational model using link prediction.
  • Evaluated candidate drugs via patient medication history and literature review.

Main Results:

  • The PDR framework maintained robust prediction capabilities, with Polygenic Risk Scores significantly influencing drug prioritization (Cohen's d = 1.05).
  • Ablation studies confirmed the crucial role of Polygenic Risk Scores (PRS).
  • Patient-specific models identified novel drug candidates missed by the foundational model, validated by medication history and literature aligned with genetic profiles.

Conclusions:

  • Demonstrates a promising approach for precision drug repurposing by integrating patient-specific data with knowledge graphs.
  • Highlights the potential of Polygenic Risk Scores in personalizing drug discovery for complex diseases.